These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 12903868)
1. Pulmonary hypertension in infancy and childhood. Gorenflo M; Nelle M; Schnabe PA; Ullmann MV Cardiol Young; 2003 Jun; 13(3):219-27. PubMed ID: 12903868 [TBL] [Abstract][Full Text] [Related]
2. Pulmonary arterial hypertension in the pediatric age. Donti A; Formigari R; Ragni L; Manes A; Galiè N; Picchio FM J Cardiovasc Med (Hagerstown); 2007 Jan; 8(1):72-7. PubMed ID: 17255821 [TBL] [Abstract][Full Text] [Related]
3. Pulmonary hypertension in the newborn. Greenough A; Khetriwal B Paediatr Respir Rev; 2005 Jun; 6(2):111-6. PubMed ID: 15911456 [TBL] [Abstract][Full Text] [Related]
4. [Therapy of primary pulmonary arterial hypertension: current status]. Solèr M Schweiz Med Wochenschr; 1994 Oct; 124(39):1701-7. PubMed ID: 7939536 [TBL] [Abstract][Full Text] [Related]
5. Abnormal vascular tone in infants and children with lung hypoplasia: Findings from cardiac catheterization and the response to chronic therapy. Keller RL; Moore P; Teitel D; Hawgood S; McQuitty J; Fineman JR Pediatr Crit Care Med; 2006 Nov; 7(6):589-94. PubMed ID: 17006391 [TBL] [Abstract][Full Text] [Related]
6. Treatment of pulmonary hypertension with selective pulmonary vasodilators. Haj RM; Cinco JE; Mazer CD Curr Opin Anaesthesiol; 2006 Feb; 19(1):88-95. PubMed ID: 16547439 [TBL] [Abstract][Full Text] [Related]
7. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Schermuly RT; Kreisselmeier KP; Ghofrani HA; Samidurai A; Pullamsetti S; Weissmann N; Schudt C; Ermert L; Seeger W; Grimminger F Circ Res; 2004 Apr; 94(8):1101-8. PubMed ID: 15031263 [TBL] [Abstract][Full Text] [Related]
8. Diagnosis and treatment of pulmonary hypertension in the adolescent. Ivy D; Eells P Adolesc Med; 2001 Feb; 12(1):79-93. PubMed ID: 11224024 [TBL] [Abstract][Full Text] [Related]
9. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Schulze-Neick I; Hartenstein P; Li J; Stiller B; Nagdyman N; Hübler M; Butrous G; Petros A; Lange P; Redington AN Circulation; 2003 Sep; 108 Suppl 1():II167-73. PubMed ID: 12970227 [TBL] [Abstract][Full Text] [Related]
10. The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use. Krasuski RA; Wang A; Harrison JK; Tapson VF; Bashore TM Am Heart J; 2005 Oct; 150(4):725-8. PubMed ID: 16209974 [TBL] [Abstract][Full Text] [Related]
11. Epoprostenol and home mechanical ventilation for pulmonary hypertension associated with chronic lung disease. Zaidi AN; Dettorre MD; Ceneviva GD; Thomas NJ Pediatr Pulmonol; 2005 Sep; 40(3):265-9. PubMed ID: 15830393 [TBL] [Abstract][Full Text] [Related]
12. Management of pulmonary arterial hypertension associated with congenital heart disease. Togănel R; Benedek I; Suteu C; Blesneac C Rom J Intern Med; 2007; 45(3):229-34. PubMed ID: 18333354 [TBL] [Abstract][Full Text] [Related]
19. Pulmonary flow reserve in children with idiopathic pulmonary arterial hypertension: implications for diagnosis and therapy. Zimmermann R; Kreuder J; Michel-Behnke I; Voelkel NF; Schranz D Eur J Med Res; 2006 May; 11(5):208-13. PubMed ID: 16723295 [TBL] [Abstract][Full Text] [Related]
20. [Primary pulmonary hypertension. An overview with special reference to risk-benefit analysis of therapy]. Schilling W Z Erkr Atmungsorgane; 1991; 177(3):117-34. PubMed ID: 1808861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]